1. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 2-2
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
2. |
Antiretrovirals: use in pregnancy reviewed |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 3-3
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
3. |
Adherence + HAART superior to mono-, dual therapy in HIV infection |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 4-4
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
4. |
Moxifloxacin IV-to-oral switch proves cost effective in patients with CAP |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 5-6
Pamela Hunter,
Preview
|
|
摘要:
An IV formulation of the new methoxyfluoroquinolone, moxifloxacin ['Avelox'; Bayer], became available recently, and has been used in the treatment of seriously ill patients hospitalised with community-acquired pneumonia (CAP). At the 10th International Congress of Infectious Diseases (ICMD), held in Singapore earlier this year, researchers presented the results of a study comparing patients with CAP who were switched from IV to oral moxifloxacin therapy as soon as their condition improved with patients who received IV, followed by oral, amoxicillin/clavulanic acid. Some patients receiving amoxicillin/clavulanic acid also received clarithromycin. Moxifloxacin proved to be clinically superior to the comparator and was also more cost effective.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
5. |
Physicians in Greece should consider atorvastatin in CHD |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 6-6
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
6. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 7-7
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
7. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 8-8
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
8. |
Aripiprazole shows advantages over established antipsychotics |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 9-11
Raewyn Poole,
Preview
|
|
摘要:
The next-generation antipsychotic aripiprazole ['Abilitat'] is at least as effective as other agents such as haloperidol, risperidone and olanzapine in the long-term treatment of schizophrenia, according to studies presented at the annual meeting of the American Psychiatric Association (APA) [Philadelphia, US; May 2002].*Furthermore, the incidences of adverse events commonly associated with antipsychotics, including extrapyramidal symptoms, bodyweight gain and elevated prolactin levels, may be reduced with aripiprazole treatment. In one study, aripiprazole demonstrated greater overall efficacy than haloperidol in the treatment of acute relapses of schizophrenia. In a second study, aripiprazole provided significant improvements, compared with placebo, in patients with stable, chronic schizophrenia.'One of the most difficult challenges in treating patients with schizophrenia is long-term adherence. Data from these studies suggest the potential for significant benefits of aripiprazole in the long-term treatment of schizophrenia',said Dr Jeffrey Lieberman from the University of North Carolina at Chapel Hill, US. A third study presented at the meeting showed that switching to aripiprazole from other antipsychotics was well tolerated, with no requirement for tapering or dose-titration, and resulted in improved or maintained control of positive and negative symptoms in patients with stable, chronic schizophrenia.
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
9. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 11-11
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|
10. |
News in brief ... |
|
Inpharma Weekly,
Volume &NA;,
Issue 1343,
2002,
Page 12-12
&NA;,
Preview
|
|
ISSN:1173-8324
出版商:ADIS
年代:2002
数据来源: ADIS
|